rs769301934

Variant summary

Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong

The NM_198586.3(NHLRC1):​c.436G>A​(p.Asp146Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000477 in 1,613,406 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D146E) has been classified as Likely pathogenic.

Frequency

Genomes: 𝑓 0.000033 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000049 ( 0 hom. )

Consequence

NHLRC1
NM_198586.3 missense

Scores

3
7
9

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:7O:1

Conservation

PhyloP100: 5.33
Variant links:
Genes affected
NHLRC1 (HGNC:21576): (NHL repeat containing E3 ubiquitin protein ligase 1) The protein encoded by this gene is a single subunit E3 ubiquitin ligase. Laforin is polyubiquitinated by the encoded protein. Defects in this intronless gene lead to an accumulation of laforin and onset of Lafora disease, also known as progressive myoclonic epilepsy type 2 (EPM2).[provided by RefSeq, Mar 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 16 ACMG points.

PM1
In a repeat NHL 1 (size 44) in uniprot entity NHLC1_HUMAN there are 13 pathogenic changes around while only 0 benign (100%) in NM_198586.3
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr6-18122169-G-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 1524781.Status of the report is criteria_provided_single_submitter, 1 stars.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.877
PP5
Variant 6-18122171-C-T is Pathogenic according to our data. Variant chr6-18122171-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 162618.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-18122171-C-T is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
NHLRC1NM_198586.3 linkuse as main transcriptc.436G>A p.Asp146Asn missense_variant 1/1 ENST00000340650.6

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
NHLRC1ENST00000340650.6 linkuse as main transcriptc.436G>A p.Asp146Asn missense_variant 1/1 NM_198586.3 P1

Frequencies

GnomAD3 genomes
AF:
0.0000328
AC:
5
AN:
152212
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000735
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000363
AC:
9
AN:
247700
Hom.:
0
AF XY:
0.0000223
AC XY:
3
AN XY:
134540
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.000100
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000628
Gnomad OTH exome
AF:
0.000165
GnomAD4 exome
AF:
0.0000493
AC:
72
AN:
1461194
Hom.:
0
Cov.:
31
AF XY:
0.0000550
AC XY:
40
AN XY:
726914
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.000115
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000567
Gnomad4 OTH exome
AF:
0.0000662
GnomAD4 genome
AF:
0.0000328
AC:
5
AN:
152212
Hom.:
0
Cov.:
33
AF XY:
0.00
AC XY:
0
AN XY:
74356
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000735
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.0000189
ExAC
AF:
0.0000494
AC:
6
EpiCase
AF:
0.000164
EpiControl
AF:
0.0000593

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingGeneDxJan 09, 2023Observed multiple times with another NHLRC1 variant in published literature, but it is not known whether the variants occurred on the same (in cis) or on different (in trans) chromosomes (Chan et al., 2003; Couarch et al., 2011; Riva et al., 2021); Published functional studies indicate that D146N interferes with the protein's ability to clear glycogen accumulation and to interact with other proteins in the glycogen synthesis pathway (Vilchez et al., 17952067; Couarch et al., 2011); In silico analysis supports that this missense variant does not alter protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 18029386, 25667860, 22425593, 25401298, 17952067, 25270369, 22047982, 21738631, 21505799, 27194917, 16529633, 29431110, 34426522, 16190947, 31589614, 33540374, 34117373, 33773408, 12958597) -
Pathogenic, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenOct 01, 2023NHLRC1: PM3:Strong, PM2, PM5, PP3, PS3:Supporting -
Pathogenic, criteria provided, single submitterclinical testingInstitute of Medical Genetics and Applied Genomics, University Hospital TübingenJun 17, 2021- -
Lafora disease Pathogenic:1Other:1
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 27, 2024This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 146 of the NHLRC1 protein (p.Asp146Asn). This variant is present in population databases (rs769301934, gnomAD 0.01%). This missense change has been observed in individual(s) with Lafora disease (PMID: 12958597, 16529633, 21505799, 22047982, 25667860). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 162618). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on NHLRC1 protein function. Experimental studies have shown that this missense change affects NHLRC1 function (PMID: 17952067, 21505799). For these reasons, this variant has been classified as Pathogenic. -
not provided, no classification providedliterature onlyGeneReviews-- -
not specified Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingGenomic Research Center, Shahid Beheshti University of Medical SciencesJul 24, 2024- -
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsMar 04, 2020The p.D146N pathogenic mutation (also known as c.436G>A), located in coding exon 1 of the NHLRC1 gene, results from a G to A substitution at nucleotide position 436. The aspartic acid at codon 146 is replaced by asparagine, an amino acid with highly similar properties. This alteration has been detected in both the homozygous and compound heterozygous states in individuals with Lafora disease who experienced later than average disease onset and atypically slow disease progression (Chan EM et al. Nat. Genet., 2003 Oct;35:125-7; Baykan B et al. Epilepsia, 2005 Oct;46:1695-7; Franceschetti S et al. Epilepsia, 2006 Mar;47:640-3; Salar S et al. Epilepsy Res., 2012 Feb;98:273-6; Ferlazzo E et al. Epilepsia, 2014 Dec;55:e129-33; Lanoiselée HM et al. Epilepsy Behav Case Rep, 2014 Jan;2:19-21; Bisulli F et al. Orphanet J Rare Dis, 2019 06;14:149). In addition, in two functional studies, this alteration was shown to impair interaction with laforin and failed to induce the degradation of protein targeting to glycogen (PTG), leading to intracellular glycogen accumulation (Couarch P et al. J. Mol. Med., 2011 Sep;89:915-25; Vilchez D et al. Nat. Neurosci., 2007 Nov;10:1407-13). Of note, these results are consistent with a finding in the malin knockout mouse, which showed glycogen accumulation underlies neurodegeration in Lafora disease (Duran J et al. Hum. Mol. Genet., 2014 Jun;23:3147-56). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Myoclonic epilepsy of Lafora 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitterclinical testingCenter for Genomic Medicine, King Faisal Specialist Hospital and Research CenterMar 26, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.37
BayesDel_addAF
Benign
-0.13
T
BayesDel_noAF
Benign
-0.24
CADD
Pathogenic
28
DANN
Uncertain
1.0
DEOGEN2
Benign
0.12
T
Eigen
Uncertain
0.42
Eigen_PC
Uncertain
0.47
FATHMM_MKL
Uncertain
0.89
D
LIST_S2
Benign
0.73
T
M_CAP
Pathogenic
0.37
D
MetaRNN
Pathogenic
0.88
D
MetaSVM
Uncertain
-0.072
T
MutationAssessor
Benign
1.4
L
MutationTaster
Benign
1.0
D
PrimateAI
Pathogenic
0.79
T
PROVEAN
Benign
-0.62
N
REVEL
Uncertain
0.40
Sift
Benign
0.29
T
Sift4G
Benign
0.17
T
Polyphen
1.0
D
Vest4
0.75
MutPred
0.80
Gain of MoRF binding (P = 0.0493);
MVP
0.95
MPC
1.0
ClinPred
0.45
T
GERP RS
5.2
Varity_R
0.16
gMVP
0.84

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs769301934; hg19: chr6-18122402; API